← All stocks

Avalo Therapeutics, Inc.

AVTX Mostly scheduled
CIK 0001534120 #2500 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$8.30M
$565.64K on a plan · $7.68M straight out of an exercise
Sold at will
$52.01K
1 of 42 sales
Net
−$8.30M
−$52.01K against sales at will

By person

11 insiders · 42 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sullivan Christopher Ryan
Chief Financial Officer
$3.52M (16) scheduled
−$3.52M
39,900
$703.03K
+3,322%
Doyle Mittie
Chief Medical Officer
$2.98M (17) scheduled
−$2.98M
51,776
$912.28K
+399.1%
VARKI PAUL
Chief Legal Officer
$1.51M (5) scheduled
−$1.51M
32,576
$573.98K
+214.0%
Goldman Jonathan
Director
$162.94K (2) scheduled
−$162.94K
3,166
$55.78K
Chan Mitchell
Director
$72.46K (1) scheduled
−$72.46K
3,166
$55.78K
Riley Jennifer
Chief Strategy Officer
$52.01K (1)
−$52.01K
37,041
$652.65K
+451.1%
NEIL GARRY ARTHUR
Chief Executive Officer
190,314
$3.35M
+317,090%
KAPLAN GILLA
Director
6,333
$111.59K
Truex Samantha
Director
6,333
$111.59K
KANTOFF AARON
Director
6,333
$111.59K
Almenoff June Sherie
Director
4,167
$73.42K

No percentages here. This company's share count has moved by a factor of 5.2 over the window, from 10,393,954 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Riley Jennifer
11 Aug 2026
Chief Strategy Officer
Sell
2,655
$19.59
$52.01K

What was left out

Form 4 filings counted 65
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 34
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 765,263
History held since 3 Oct 2016